Skip to content Skip to search

Republish This Story

* Please read before republishing *

We’re happy to make this story available to republish for free under an Attribution-NonCommercial-NoDerivatives Creative Commons license as long as you follow our republishing guidelines, which require that you credit The 19th and retain our pixel. See our full guidelines for more information.

To republish, simply copy the HTML at right, which includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to The 19th. Have questions? Please email [email protected].

— The Editors

Loading...

Modal Gallery

/
All donations doubled!

Menu

  • Our Mission
  • Our Team
  • Latest Stories
  • Search
  • Upcoming Events
  • Contact Us
  • Newsletter
  • Donate
  • Work With Us
  • Fellowships
    • From the Collection

      Changing Child Care

      Illustration of a woman feeding a baby a bottle
      • The full PUMP Act is now in effect. Here’s what it does for lactating parents.

        Chabeli Carrazana · April 28
      • 1 in 4 parents report being fired for work interruptions due to child care breakdowns

        Chabeli Carrazana · February 2
      • Washington, D.C., offers financial relief to local child care workers

        Orion Rummler · September 20
    • From the Collection

      Next-Gen GOP

      Illustration of a woman riding an elephant
      • Mayra Flores’ victory set a record for women in Congress. It also reflects the growing visibility of Republican Latinas

        Candice Norwood · June 21
      • A banner year for Republican women

        Amanda Becker · November 11
      • Republican women could double representation in the U.S. House

        Amanda Becker · November 4
    • From the Collection

      On The Rise

      Illustration of three women marching
      • A train derailment spilled toxic chemicals in her Ohio town. Now she’s running for mayor.

        Jessica Kutz · November 6
      • This Delaware candidate could be the first transgender member of Congress

        Orion Rummler · June 26
      • Can Cheri Beasley build a winning coalition in North Carolina?

        Candice Norwood · October 11
    • From the Collection

      Pandemic Within a Pandemic

      Illustration of four people marching for Black Lives Matter with coronavirus as the backdrop
      • Some LGBTQ+ people worry that the COVID-19 vaccine will affect HIV medication. It won’t.

        Orion Rummler · November 23
      • Why are more men dying from COVID? It’s a complicated story of nature vs. nurture, researchers say

        Mariel Padilla · September 22
      • Few incarcerated women were released during COVID. The ones who remain have struggled.

        Candice Norwood · August 17
    • From the Collection

      Portraits of a Pandemic

      Illustration of a woman wearing a mask and holding up the coronavirus
      • For family caregivers, COVID is a mental health crisis in the making

        Shefali Luthra · October 8
      • A new database tracks COVID-19’s effects on sex and gender

        Shefali Luthra · September 15
      • Pregnant in a pandemic: The 'perfect storm for a crisis'

        Shefali Luthra · August 25
    • From the Collection

      The 19th Explains

      People walking from many articles to one article where they can get the context they need on an issue.
      • The 19th Explains: How guns and domestic violence intersect in a Supreme Court case

        Jennifer Gerson · November 1
      • The 19th Explains: What to know about Ohio Issue 1

        Grace Panetta · October 16
      • The 19th Explains: The groundwork for a Supreme Court case on gender-affirming care is being laid now

        Orion Rummler · October 12
    • From the Collection

      The Electability Myth

      Illustration of three women speaking at podiums
      • Mayra Flores’ victory set a record for women in Congress. It also reflects the growing visibility of Republican Latinas

        Candice Norwood · June 21
      • Stepping in after tragedy: How political wives became widow lawmakers

        Mariel Padilla · May 24
      • Do term limits help women candidates? New York could be a new testing ground

        Barbara Rodriguez · January 11
    • From the Collection

      The Impact of Aging

      A number of older people walking down a path of information.
      • From ballroom dancing to bloodshed, the older AAPI community grapples with gun control

        Nadra Nittle, Mariel Padilla · January 27
      • 'I'm planning on working until the day I die': Older women voters are worried about the future

        Mariel Padilla · June 3
      • Climate change is forcing care workers to act as first responders

        Jessica Kutz · May 31
    • From the Collection

      The State of Our Nation

      • Democracy is a kitchen table issue

        Errin Haines · September 21
    • From the Collection

      Voting Rights

      A series of hands reaching for ballots.
      • Voting organizers are breathing ‘a deep sigh of relief’ over Supreme Court rulings on elections — for now

        Barbara Rodriguez · July 6
      • Ranked-choice voting is gaining momentum. So are efforts to stop it.

        Barbara Rodriguez · April 24
      • Connecticut voters approved early voting. Here’s how their new secretary of state wants to make it happen.

        Barbara Rodriguez · February 13

    View all collections

  • Explore by Topic

    • 19th Polling
    • Abortion
    • Business & Economy
    • Caregiving
    • Coronavirus
    • Education
    • Election 2020
    • Election 2022
    • Election 2024
    • Environment & Climate
    • Health
    • Immigration
    • Inside The 19th
    • Justice
    • LGBTQ+
    • Military
    • Politics
    • Press Release
    • Race
    • Sports
    • Technology

    View All Topics

Home
  • Our Mission
  • Our Team
  • Latest Stories
  • Search
  • Upcoming Events
  • Contact Us
  • Newsletter
  • Donate
  • Work With Us
  • Fellowships

We’re an independent, nonprofit newsroom reporting on gender, politics and policy. Read our story.

Fall Member Drive

Support the nonprofit news you trust through the critical moments that shape our democracy and our lives.

Donate Today

The 19th thanks our sponsors. Become one.

People march through downtown Amarillo, Texas to protest a lawsuit to ban the abortion drug mifepristone.
People march through downtown Amarillo, Texas to protest a lawsuit to ban the abortion drug mifepristone in February 2023. (Justin Rex/AP)

Abortion

Court rules mifepristone can remain available, but with tightened restrictions

The 5th Circuit ruled Wednesday that mifepristone, a pill used in medication abortions, can remain on the market. But restrictions in the ruling could present hurdles for abortion access.

By

Rebekah Barber, Mariel Padilla

Published

2023-04-13 09:49
9:49
April 13, 2023
am

Share

  • Twitter
  • Facebook
  • Email

Your trusted source for contextualizing the news. Sign up for our daily newsletter.

Mifepristone, one of two drugs typically used to induce a medication abortion, will remain available for now but with significant restrictions. Those include limiting the drug’s usage to up to seven weeks of pregnancy and barring its distribution by mail. 

The U.S. Court of Appeals for the 5th Circuit on Wednesday night put on hold part of a lower court’s ruling to withdraw decades-old Food and Drug Administration approval of mifepristone, which could have effectively banned the drug from distribution. Currently, more than half of all abortions in the United States are medication abortions, according to the latest Guttmacher Institute data. 

The 19th thanks our sponsors. Become one.

After the Texas-based federal judge’s decision Friday, the Justice Department quickly appealed. In its filings, the Justice Department argued that withdrawing FDA approval from mifepristone would severely harm patients across the country. They also argued the ruling would allow doctors to challenge FDA approval of any drug or federal action that allegedly injures third parties. 

In its decision, the 5th Circuit raised concerns about whether the statute of limitations enabled the plaintiffs to challenge the approval of the drug, which has been approved by the FDA since 2000, but they did consider the plaintiffs’ more timely challenges. For decades, mifepristone was subject to restrictions: The medication could be dispensed by only certified prescribers in clinics, medical offices or hospitals — not pharmacies — and patients had to sign an agreement stating they were warned about potential side effects. 

In recent years, regulatory changes started allowing mifepristone to be accessed by a wider range of people. In 2016, the gestation period in which the drug can be used was lengthened to 10 weeks. In April 2021, due to the pandemic, the FDA announced it would allow abortion pills to be mailed to patients. Then, in December 2021, the FDA issued a permanent decision to allow mailing of the pills and expanded access through pharmacies.  

  • More from The 19th
    An exam table is seen at a Planned Parenthood Health Center in Louisville, Kentucky.
  • If mifepristone is blocked, access to medication abortion pills could vary by state — or even by clinic
  • ‘There’s nowhere to hide’: Abortion rights advocates want drug ruling to define the GOP in 2024

These are the same changes that the 5th Circuit struck down in its 42-page order. In a 2-to-1 vote, the court ruled that the drug could be used only up to seven weeks instead of 10, and it can no longer be distributed by mail, raising concerns from abortion rights advocates that it will be much harder to access — particularly for people in states where abortion is banned or severely restricted, who are often traveling out of state to access the procedure. 

Since mifepristone was first made available in 2000, it has allowed millions of pregnant people to have access to safe abortions that are often less expensive to perform than surgical abortions.

Clinics that have been flooded with out-of-state patients have leaned on medication abortions to allow them to serve as many patients as possible. Restrictions on how late in pregnancy the drug can be administered and how — under the ruling, dispensing it by telemedicine is barred — could add additional hurdles and lead to increased wait times. 

Sylvia Ghazarian, executive director of Women’s Reproductive Rights Assistance Project, a nonprofit organization that helps people obtain funds for abortions or emergency contraceptives, said that 70 percent of the patients they have helped obtain abortions used medications. Seventy-five percent of the people they serve are people of color.

Ghazarian said that forcing the communities that they serve to go into clinics — instead of the lower-cost and more private option of receiving the drug via mail — will significantly impact access. 

“Access has always been an issue for marginalized communities because a clinic is not necessarily in a location that is easily accessible,” Ghazarian said. “Many have to travel 60 miles or more to get to a clinic, which adds to the domino effect of taking time off work, child care issues and all of the practical support-type challenges that an individual may also be facing.”

It is unclear how this decision will impact clinics’ process for administering medication abortions. Medication abortions can still be carried out only using misoprostol, the drug typically used in tandem with mifepristone. However, the one-pill regimen is less effective than the combination of drugs. 

Kimberly Inez McGuire, the executive director of Unite for Reproductive and Gender Equity, a reproductive rights advocacy group, called the Texas ruling a “stunning overreach.” 

“The fight is not over, and the implications of this latest decision are not yet clear,” McGuire said. “What we do know is that mifepristone remains safe, effective and an essential part of abortion care.”

The Biden administration has been vocal about its desire to keep mifepristone on the U.S. market and as readily available to patients as possible. At a White House Task Force on Reproductive Healthcare Access meeting on Wednesday, ahead of the appeal ruling, Vice President Kamala Harris warned about the potential long-lasting implications of the Texas district court ruling. 

“We have in effect a situation where politicians and politics have driven lawyers to go to a court of law where a judge, who is not a medical professional, is making a decision to undo the ruling of over 20 years ago of the FDA, that declared a specific medication safe and effective for the American people,” Harris said. “So one must appreciate that when we think about the integrity of our health care delivery systems. Attacking the very credibility of the FDA on this one matter for the sake of politics and a political agenda can have wide, sweeping ramifications.” 

Attorney General Merrick Garland said at the same meeting that the Justice Department “strongly disagrees” with the Texas court’s unprecedented decision. 

“The Justice Department will continue to defend the FDA approval of mifepristone, as well as the FDA’s role as the expert body that Congress has designated to make decisions about the safety and efficacy of prescription medicines in this country.” 

Grace Panetta contributed to this report. 

Share

  • Twitter
  • Facebook
  • Email

Fall Member Drive

Support the nonprofit news you trust through the critical moments that shape our democracy and our lives.

Donate Today

Up Next

Iowa Gov. Kim Reynolds speaks with journalists at The Iowa State Capitol in Des Moines, Iowa in March 2022.

Politics

A rift is growing in the Republican Party over birth control

Iowa is one of several red states that has attempted to pass legislation to expand birth control access — but some anti-abortion groups oppose the move.

Read the Story

The 19th
The 19th is a 501(c)(3) tax-exempt organization. Our stories are free to republish in accordance with these guidelines.

  • Donate
  • Newsletter
  • Events
  • Search
  • Jobs
  • Fellowships
  • Contact Us
  • About Us
  • Community Guidelines
  • Membership
  • Membership FAQ
  • Ways to Give
  • Sponsorship
  • Privacy
  • Twitter
  • Facebook
  • Instagram